dihydrogenistin: from soybeans; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
dihydrogenistin : A hydroxyisoflavanone that is dihydrogenistein in which the phenolic hydrogen at position 7 has been replaced by a beta-D-glucosyl residue. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11070108 |
| CHEMBL ID | 518255 |
| CHEBI ID | 133413 |
| SCHEMBL ID | 572117 |
| MeSH ID | M0438021 |
| Synonym |
|---|
| dihydrogenistin |
| CHEBI:133413 |
| 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-3,4-dihydro-2h-1-benzopyran-7-yl beta-d-glucopyranoside |
| dihydrogenistein 7-o-beta-d-glucoside |
| dihydrogenistein 7-o-beta-d-glucopyranoside |
| 441045-21-2 |
| CHEMBL518255 |
| SCHEMBL572117 |
| 5-hydroxy-3-(4-hydroxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrochromen-4-one |
| 7-(beta-d-glucopyranosyloxy)-2,3-dihydro-5-hydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-one |
| DTXSID101122814 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| beta-D-glucoside | Any D-glucoside in which the anomeric centre has beta-configuration. |
| hydroxyisoflavanone | Any member of the class of isoflavanones with at least one hydroxy substituent. |
| monosaccharide derivative | A carbohydrate derivative that is formally obtained from a monosaccharide. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID334603 | Cytotoxicity against human Hs 742.T cells after 6 days by MTT assay | 2002 | Journal of natural products, Jun, Volume: 65, Issue:6 | New isoflavone and triterpene glycosides from soybeans. |
| AID334600 | Cytotoxicity against human Hs 740.T cells after 6 days by MTT assay | 2002 | Journal of natural products, Jun, Volume: 65, Issue:6 | New isoflavone and triterpene glycosides from soybeans. |
| AID334605 | Cytotoxicity against human LNCaP-FGC cells after 6 days by MTT assay | 2002 | Journal of natural products, Jun, Volume: 65, Issue:6 | New isoflavone and triterpene glycosides from soybeans. |
| AID334602 | Cytotoxicity against human Hs 578T cells after 6 days by MTT assay | 2002 | Journal of natural products, Jun, Volume: 65, Issue:6 | New isoflavone and triterpene glycosides from soybeans. |
| AID334601 | Cytotoxicity against human Hs 746T cells after 6 days by MTT assay | 2002 | Journal of natural products, Jun, Volume: 65, Issue:6 | New isoflavone and triterpene glycosides from soybeans. |
| AID334604 | Cytotoxicity against human DU145 cells after 6 days by MTT assay | 2002 | Journal of natural products, Jun, Volume: 65, Issue:6 | New isoflavone and triterpene glycosides from soybeans. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||